Evidence map›Paper›PMID 26062785›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2016

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.

Neal R Swerdlow, Savita Bhakta, Hsun-Hua Chou, Jo A Talledo, Bryan Balvaneda, Gregory A Light

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02634684 (Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02634684 phase2completednot on this map

Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis

TypeinterventionalSponsorUniversity of California, San DiegoRan2014 to 2020Enrolled82ConditionsSchizophreniaArmsDextroamphetamine, Placebo
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Glutamatergic Modulation of Brain Function in Psychosis: A Systematic Review of Neuroimaging Studies.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Memantine effects on auditory discrimination and training in schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  10. Trial
  11. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Trial
  12. Trial
  13. Article
  14. Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Neal R SwerdlowDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Savita BhaktaDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Hsun-Hua ChouDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Jo A TalledoDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Bryan BalvanedaDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Gregory A LightDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
University of California, San Diego · US

Funding

Pharmacologic augmentation of neurocognition and cognitive training in psychosisR01MH059803 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 1999 to 2018
$4.5M
Memantine effects on sensorimotor gating and neurocognition in schizophreniaR01MH094320 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2012 to 2020
$2.6M
Biomarker Strategies for Medication-Enhanced Cognitive Training in SchizophreniaR34MH093453 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2011 to 2013
$689k
NIMH NIH HHS MH59803NIMH NIH HHS MH93453NIMH NIH HHS MH94320NIMH NIH HHS R01 MH059803NIMH NIH HHS R01 MH094320NIMH NIH HHS R34 MH093453
6 · The paper itself

Abstract

Patients with chronic psychotic disorders (CPD) exhibit deficient sensorimotor gating (measured by prepulse inhibition (PPI) of startle) and mismatch negativity (MMN). In healthy subjects (HS), N-methyl-D-aspartate (NMDA) antagonists like memantine and ketamine increase PPI, and under some conditions, memantine enhances MMN; these findings present a challenge to understanding the basis for deficient PPI and MMN in psychotic disorders, as reduced NMDA activity is implicated in the pathogenesis of these disorders. Here we assessed for the first time the effects of memantine on PPI and MMN in CPD subjects. Baseline PPI was measured in HS and patients with a diagnosis of schizophrenia or schizoaffective disorder, depressed type. Subjects (total n=84) were then tested twice, in a double-blind crossover design, comparing either: (1) placebo vs 10 mg of memantine or (2) placebo vs 20 mg memantine. Tests included measures of acoustic startle magnitude and habituation, PPI, MMN, autonomic indices, and subjective self-rating scales. Memantine (20 mg) significantly enhanced PPI in CPD subjects, and enhanced MMN across subject groups. These effects on PPI were age dependent and most evident in older CPD patients, whereas those on MMN were most evident in younger subjects. The lower dose (10 mg) either had no detectable effect or tended to degrade these measures. The NMDA antagonist, memantine, has dose-dependent effects on preconscious, automatic measures of sensorimotor gating and auditory sensory processing that are associated with enhanced cognition and function in CPD patients. Ongoing studies will determine whether these memantine-induced changes predict acute pro-cognitive or otherwise clinically beneficial effects in CPD patients.

Indexed as

AdultCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHabituation, PsychophysiologicHumansMaleMemantinePsychotic DisordersPsychotropic DrugsSchizophreniaSchizophrenic PsychologySensory GatingMemantinePsychotropic Drugs

Identifiers

PMID26062785
PMCPMC5130118
OpenAlexW1590457702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.